Excellent to see some solid results for rosacea which pave the way to Ph3 and commercialisation. Rosacea being treatable but largely incurable means ongoing need and a self-sustaining target market, which is much more lucrative than shorter-term dermatitis. Good news. Well done BOT on a great ann. GLTA
Ann: Positive BTX 1702 Phase 1b/2 Clinical Study for Rosacea, page-29
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
0.015(4.35%) |
Mkt cap ! $651.6M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 36.5¢ | 34.5¢ | $1.231M | 3.443M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 156338 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 444065 | 17 |
View Market Depth
| Last trade - 16.10pm 22/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |